Actively Recruiting
Evaluating Tabellvi4 Adalimumab for Moderate to Severe Crohns Disease in Chinese Adults in a Real-World Setting
Led by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Updated on 2026-09-24
50
Participants Needed
7
Research Sites
12 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of Tabellvi4 Adalimumab Injection in Chinese adults with moderate to severe active Crohns disease. This post-marketing, real-world study is designed as a single-arm trial enrolling 50 participants. The research focuses on measuring adverse events and clinical remission rates over time. Participants receive an initial induction dose of 160 mg at Week 0, followed by 80 mg at Week 2. After induction, a maintenance dose of 40 mg is given by subcutaneous injection every two weeks. The study monitors participants for up to 54 weeks, with key evaluations at Week 26 and additional assessments at Weeks 4, 12, and 52. During the study, participants undergo regular clinical assessments including the Crohns Disease Activity Index CDAI to track remission and response. Laboratory tests such as C-reactive protein and fecal calprotectin are collected at specified intervals. Researchers also monitor for serious adverse events and drug reactions throughout the 54-week period to evaluate safety and treatment impact.
CONDITIONS
Brief Title
Treatment of Chinese Adult Subjects With Moderate to Severe Crohn's Disease With Tabellvi®
Research Team
J
Jun Shen, Doctor
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here